当前位置: 首页 > 期刊 > 《医学信息》 > 202015
编号:13844668
二代测序技术检测新疆地区NSCLC患者基因类型及临床意义(4)
http://www.100md.com 2020年4月16日 《医学信息》 202015
     [10]Cross DAE,Ashton SE,Ghiorghiu S,et al.AZD9291,an irreversible EGFR TKI,overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J].Cancer Discovery,2014,4(9):1046-1061.

    [11]Korpanty GJ,Graham DM,Vincent MD,et al.Biomarkers that currently affect clinical practice in lung cancer:EGFR,ALK,MET,ROS-1,and KRAS[J].Frontiers in Oncology,2014(4):204.

    [12]Li T,Kung HJ,Mack PC,et al.Genotyping and genomic profiling of non–small-cell lung cancer:implications for current and future therapies[J].Journal of Clinical Oncology,2013,31(8):1039.

    [13]Janne PA,Shaw AT,Camidge DR,et al.Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer:Results of a Phase I Study[J].Journal of Thoracic Oncology,2016,11(5):737-747.

    [14]Hirsch FR,Scagliotti GV,Mulshine JL,et al.Lung cancer:current therapies and new targeted treatments[J].The Lancet,2017,389(10066):299-311.

    [15]Ju L,Han M,Zhao C,et al.EGFR,KRAS and ROS1 variants coexist in a lung adenocarcinoma patient[J].Lung Cancer,2016(95):94-97.

    收稿日期:2020-06-02;修回日期:2020-06-28

    編辑/肖婷婷, 百拇医药(顾国民 朱晓丹 朱红革 刘春玲)
上一页1 2 3 4